Wolfe Research reiterates Outperform on BioMarin stock at $95 By Investing.com

BioMarin will discontinue dosing and enrollment for Voxzogo in phase 2 trials for Turner Syndrome, SHOX-deficiency and ACAN-deficiency — a move Wolfe Research says only affects ~1–4% of projected 2032–2036 global sales and is not material to topline. Wolfe reiterated an Outperform with a $95 price target; analyst targets range from $62 (Leerink) to $105 (Barclays) with BofA at $85 and Jefferies at $103; shares trade at $57.82 with a ~$11.06B market cap. The firm reported positive Phase 1/2 BMN 351 data showing dose-dependent increases in dystrophin (notable at 9 mg/kg) and VOXZOGO growth/proportionality improvements in early-treated children, supporting pipeline upside despite the discontinued indications.

Analysis

The operational choice to tighten the program slate is a de-risk from an expense and resource-allocation perspective: freeing CMO/CRO capacity and R&D spend can accelerate higher-impact assets and shorten time-to-next-readout by quarters. That reallocation raises gross margin optionality for the firm even if near-term revenue guidance is unchanged, because a single successful late-stage asset can leverage existing commercial infrastructure with disproportionately high incremental margin.

Competitively, mid-cap rare-disease peers and acquirers are the indirect beneficiaries — valuation arbitrage opens if the market begins to re-rate the company as a lower-burn, higher optionality biotech rather than a broad pediatric franchise builder. Conversely, specialty suppliers (small-scale fill/finish CMOs tied to specific indications) face lost volumes; larger, flexible CMOs should capture the freed capacity and pick up incremental revenue within 3–9 months.

Key catalysts and tail risks are binary and time-staggered: near-term (weeks–months) analyst revisions and positioning flows can drive 10–25% price moves; medium-term (6–18 months) clinical readouts or partnering/asset sales will create 2x re-rating potential or a comparable downside if negative; long-term (2–5 years) reimbursement and label breadth determine peak sales and valuation multiples. A contrarian point: the market underprices the combination of cash-flow improvement plus upside from a single successful neuromuscular program — that asymmetry makes structured optionality trades preferable to naked directional exposure.

Key Decisions for Investors

• Tactical long BMRN equity on weakness: accumulate on a >15% intraday drop from current levels, target 60–100% upside over 12–24 months if the lead neuromuscular program posts positive dose-response; use a 30% hard stop from entry to cap downside. Rationale: lower burn + concentrated upside if clinical execution continues.
• Options asymmetric: buy 12–18 month LEAPS calls ~25–35% OTM for limited upfront cost (max loss = premium) to capture binary upside from upcoming readouts, funded by selling 3–6 month calls ~10% ITM to reduce net premium. Expect 3:1 to 5:1 payoff if positive data, loss limited to premium if negative.
• Relative-value pair: long BMRN / short XBI (equal notional) for a 6–12 month trade to isolate idiosyncratic upside vs sector weakness. Take profits if spread outperforms by 40–60% or cut if underperformance exceeds 25%, as this neutralizes broader biotech beta.
• Event-hedge ahead of pivotal announcements: buy 3–6 month puts ~20–25% OTM to protect existing exposure during binary readouts; works if you want to retain long optionality while capping downside risk from surprise negative data.